"Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy”
Application 78/CHENP/2004 published 2005-12-09, filed 2004-01-13
Methods and kits for diagnosing tumorigenicity and for determining whether a cancer patient is resistant to the pharmacological effects of antiestrogen therapy. Increased levels of the PCDGF (GP88) growth factor are indicative of tumorigenicity and resistance to the pharmacological effects of antiestrogen therapy. The methods and kits of the invention are useful for assessing the tumorigencity of a biological sample from a patient and determining whether the patient is a candidate for antiestrogen, including tamoxifen, therapy.
Applicant
A & G PHARMACEUTICALS, INC
600 E. Lombard Street, Suite 509, Baltimore, MD 21202, a US company, USA
Inventor
International Info
Classification: A61B
Publication Number: PCT/US02/18549
Priority Information
09/880,842 US 2001-06-15